Treatment of resistant cancers by administering Anti- her2 antibody-drug conjugates

An antibody-drug conjugate with a specific drug-linker structure effectively targets and treats HER2-expressing cancers resistant to existing anti-HER2 drugs, addressing secondary resistance and inherent resistance in breast and gastric cancers, among others.

JP2026035673APending Publication Date: 2026-03-04DAIICHI SANKYO CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2025201784
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-09-08
Filing Date
2025-11-21
Publication Date
2026-03-04

AI Technical Summary

Technical Problem

Existing anti-HER2 drugs are ineffective against HER2-expressing cancers that have developed resistance or refractory status, including secondary-resistant cancers and those with inherent resistance, such as breast, gastric, and other solid tumors.

Method used

An antibody-drug conjugate linking an anti-HER2 antibody with a specific drug-linker structure, represented by -(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX), is developed to target and treat HER2-expressing cancers resistant to existing anti-HER2 drugs.

Benefits of technology

The antibody-drug conjugate exhibits excellent antitumor effects against HER2-expressing cancers that are resistant or refractory to existing treatments, demonstrating high safety and efficacy in preclinical and clinical studies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026035673000001_ABST
    Figure 2026035673000001_ABST
Patent Text Reader

Abstract

To provide a therapeutic agent and a therapeutic method effective for HER2-expressing cancers resistant or refractory to existing anti-HER2 drugs.SOLUTION: Provided are a therapeutic agent and a therapeutic method for HER2-expressing cancers that are resistant or refractory to existing anti-HER2 drugs using an antibody-drug conjugate in which a linker represented by the formula: - (Succinimid-3-yl-N) -CH2CH2CH2CH2CH2-C (= O) -GGFG-NH-CH2-O-CH2-C (= O) - (NH-DX) and a drug are bound to an anti-HER2 antibody.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Hexacyclic compound

    JP1993059061A

  • Condensed six-membered cyclic amino compound, medicine containing the same and production of the same

    JP1996337584A

  • Monoclonal antibodies directed to the HER2 receptor

    US5677171A

  • Immunoglobulin variants

    US5821337A

  • Drug complexes

    WO1997046260A1